You are here

  • Home
  • Archive
  • Volume 68, Issue 5
  • European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research

Article Text

Article menu
Download PDFPDF
Recommendations
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research
  1. J Avouac1,
  2. O Kowal-Bielecka2,
  3. R Landewe3,
  4. S Chwiesko2,
  5. I Miniati4,
  6. L Czirjak5,
  7. P Clements6,
  8. C Denton7,
  9. D Farge8,
  10. K Fligelstone9,
  11. I Földvari10,
  12. D E Furst6,
  13. U Müller-Ladner11,
  14. J Seibold12,
  15. R M Silver13,
  16. K Takehara14,
  17. B Garay Toth15,
  18. A Tyndall16,
  19. G Valentini17,
  20. F van den Hoogen18,
  21. F Wigley19,
  22. F Zulian20,
  23. M Matucci-Cerinic4,
  24. and EUSTAR coauthors
  1. 1 Rheumatology A Department, RDU, Paris, France
  2. 2 Rheumatology Department, Medical University, Bialystok, Poland
  3. 3 Rheumatology Department, University Hospital, Maastricht, Netherlands
  4. 4 Rheumatology Department, UF, Florence, Italy
  5. 5 Rheumatology Department, University of Pecs, Pecs, Hungary
  6. 6 Rheumatology Department, University of California Los Angeles, Los Angeles, California, USA
  7. 7 Rheumatology Department, Royal Free Hospital, London, UK
  8. 8 Internal Medicine Department, Hopital St Louis, Paris, France
  9. 9 Scleroderma Association, Federation European Scleroderma Associations (FESCA), Harlesden, UK
  10. 10 Rheumatology Department, Klinik Eilbek, Hamburg, Germany
  11. 11 Rheumatology Department, University of Giessen, Bad Nauheim, Germany
  12. 12 Rheumatology Department, University of Michigan, Ann Arbor, Michigan, USA
  13. 13 Rheumatology Department, Medical University of South Carolina, Charleston, Virginia, USA
  14. 14 Dermatology Department, University School of Medicine, Kanazawa, Japan
  15. 15 Federation European Scleroderma Associations (FESCA), Budapest, Hungary
  16. 16 Rheumatology Department, University Hospital, Basel, Switzerland
  17. 17 Rheumatology Department, Second University, Naples, Italy
  18. 18 Rheumatology Department, Radboud University Medical Center, Nijmegen, Netherlands
  19. 19 Rheumatology Department, John Hopkins University, Baltimore, Maryland, USA
  20. 20 Rheumatology Department, University of Padua, Padua, Italy
  1. M Matucci-Cerinic, Department of Biomedicine, Division of Rheumatology, University of Florence, Villa Monna Tessa, Viale G Pieraccini 18, 50134, Florence, Italy; cerinic{at}unifi.it

Abstract

Objective: To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail.

Methods: In agreement with the EULAR standard operating procedures a Task Force was created that consisted of the EUSTAR board members, 10 systemic sclerosis (SSc) experts invited from outside the EUSTAR board and representing Europe, the USA and Japan, a clinical epidemiologist, 2 patients with SSc and 3 fellows for literature research. All EUSTAR centres were invited to contribute to the development of recommendations through submission and preliminary selection of the research questions. The systematic literature research was performed using the Pubmed, Medline, EMBASE and Cochrane databases. Retrieved trials were evaluated according to the Jadad classification, and the level of evidence was graded from 1 to 4. Outcome data for efficacy and adverse events were abstracted and effect size, number needed to treat (NNT) and number needed to harm (NNH) were calculated when appropriate.

Results: In all, 65 EUSTAR Centres provided 304 research questions concerning SSc treatment. These questions were aggregated, subdivided into 19 treatment categories and then subjected to preliminary selection by a web-based Delphi technique. The final set of 26 research questions was created by the Expert Committee based on the results of the Delphi exercise and the expert’s experience.

Conclusions: This paper is a comprehensive summary of the methods we used to build recommendations for the drug treatment of systemic sclerosis, combining an evidence based approach and expert opinion.

https://doi.org/10.1136/ard.2008.095299

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes